Wealth Enhancement Advisory Services LLC Acquires 11,262 Shares of Axon Enterprise, Inc $AXON

Wealth Enhancement Advisory Services LLC raised its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 93.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,365 shares of the biotechnology company’s stock after buying an additional 11,262 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Axon Enterprise were worth $13,270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AXON. Newbridge Financial Services Group Inc. increased its position in shares of Axon Enterprise by 2.8% in the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 14 shares during the last quarter. Vicus Capital lifted its position in Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 14 shares during the last quarter. Evergreen Capital Management LLC grew its stake in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares in the last quarter. Blue Trust Inc. grew its stake in Axon Enterprise by 2.5% in the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after buying an additional 16 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC increased its holdings in shares of Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 2.1%

AXON opened at $450.46 on Friday. The company has a market cap of $36.22 billion, a P/E ratio of 296.36, a P/E/G ratio of 9.82 and a beta of 1.46. The business’s 50-day moving average price is $506.17 and its 200-day moving average price is $594.01. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.08 EPS. On average, equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AXON. Piper Sandler lowered their price objective on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Robert W. Baird set a $800.00 price objective on Axon Enterprise in a report on Wednesday, February 25th. Finally, Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective on the stock in a report on Tuesday, January 6th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Insiders Place Their Bets

In other Axon Enterprise news, Director Erika Nardini sold 198 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total transaction of $100,302.84. Following the completion of the transaction, the director owned 1,946 shares of the company’s stock, valued at $985,804.68. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeri Williams sold 157 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director owned 1,159 shares of the company’s stock, valued at approximately $567,910. This trade represents a 11.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 23,855 shares of company stock worth $13,299,928. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.